Pulmonary Embolism for the Med-Surg Nurse
Medical-Surgical Nursing: Recognition, Treatment, Monitoring & Post-ICU Care
NursingAlgorithm.com • Nursing Education Resource
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| HIGH-YIELD TAKEAWAY A pulmonary embolism is a venous thromboembolism that obstructs pulmonary arterial blood flow. For the bedside nurse, the immediate priorities are recognizing deterioration, supporting oxygenation and circulation, administering/monitoring ordered anticoagulation, watching closely for bleeding, and identifying right-ventricular strain or hemodynamic instability. |
1. What Is a Pulmonary Embolism?
A pulmonary embolism (PE) occurs when material—most commonly a thrombus arising from a deep vein in the lower extremity or pelvis—travels through the venous circulation and lodges in the pulmonary arterial system. PE and deep-vein thrombosis (DVT) are manifestations of venous thromboembolism (VTE). The clinical effect depends less on the clot’s anatomic label alone than on the amount of vascular obstruction, the patient’s cardiopulmonary reserve, and the degree of right-ventricular (RV) stress or failure.
Basic Pathophysiology
- Venous thrombus forms → embolizes → travels through the right heart → lodges in the pulmonary arterial circulation.
- Pulmonary vascular obstruction increases pulmonary vascular resistance and can create ventilation-perfusion mismatch, producing hypoxemia and dyspnea.
- In a significant PE, the RV must pump against an acutely increased afterload. RV dilation and reduced RV output can decrease left-ventricular filling and systemic cardiac output.
- Severe RV failure can progress to hypotension, obstructive shock, syncope, cardiac arrest, and death.
- PE may also cause pleuritic pain or hemoptysis when peripheral pulmonary vessels and adjacent tissue are affected.
| CLINICAL PEARL Do not equate ‘large clot’ with ‘high-risk PE.’ Contemporary risk assessment focuses heavily on hemodynamic status, RV dysfunction, biomarkers, clinical severity, and the patient’s overall physiologic response. |
2. Risk Factors: Think Virchow’s Triad
| Mechanism | Examples |
| Venous stasis | Immobility, prolonged hospitalization, long travel, paralysis, heart failure |
| Endothelial injury | Recent surgery, trauma, vascular injury, indwelling venous devices |
| Hypercoagulability | Active cancer, pregnancy/postpartum state, estrogen exposure, inherited/acquired thrombophilia |
Additional important risk factors include prior VTE, increasing age, obesity, inflammatory illness, and certain medications or medical conditions. Some PEs occur without an immediately identifiable provoking factor.
3. Assessment: What the Nurse Should Look For
| Assess | What to monitor / why it matters |
| Respiratory | Dyspnea, tachypnea, work of breathing, SpO₂, breath sounds, pleuritic chest pain, hemoptysis, may have respiratory alkalosis |
| Cardiovascular | Heart rate/rhythm, blood pressure, peripheral perfusion (Capillary refill, skin color compared to baseline), chest pain, syncope/presyncope |
| Neurologic | Mental status, new confusion, agitation, syncope, reduced responsiveness—possible consequences of hypoxemia or poor perfusion |
| Peripheral vascular | Unilateral swelling, warmth, tenderness, or asymmetry suggesting DVT |
| Overall trajectory | Compare current findings with baseline; worsening tachycardia, oxygen requirement, hypotension, or mental status may signal deterioration |
4. Diagnostic Workup: Know What the Tests Are Doing
- Clinical probability tools such as Wells or Geneva help estimate the pretest probability of PE; they do not independently diagnose PE.
- D-dimer can help exclude PE in appropriately selected patients with low/intermediate pretest probability; it is nonspecific and can be elevated for many reasons.
- CT pulmonary angiography (CTPA) is the principal imaging test used to confirm acute PE when appropriate.
- V/Q scanning is an alternative when CTPA is unsuitable or when specific clinical circumstances favor it.
- ECG may show nonspecific changes and is useful for evaluating competing diagnoses and cardiac strain.
- Troponin and natriuretic peptides may help identify myocardial/RV stress and contribute to risk stratification.
- Echocardiography is especially useful for assessing RV function and hemodynamic impact in patients with more severe disease.
| NURSING FOCUS A nurse may be the first person to recognize that a patient’s physiology is worsening while the diagnostic label is still evolving. Trend the patient—not just the individual test result. |
5. Common Treatment Options on the Medical-Surgical Unit
| Therapy | Purpose | Nursing considerations |
| Anticoagulation | Prevents clot extension and new thrombus formation while the body works to resolve the clot. | Verify medication, dose, timing, renal/hepatic considerations as applicable; monitor for bleeding and ordered laboratory parameters; reinforce adherence. |
| DOAC therapy | Oral anticoagulation for many eligible patients after acute PE (Generally a minimum of 3 months). | Assess bleeding risk, medication reconciliation, adherence, interactions, renal function when relevant, and discharge understanding. |
| UFH / LMWH | Parenteral anticoagulation used in selected acute-care situations. | Monitor ordered coagulation parameters for UFH and platelet trends/bleeding as appropriate; inspect injection sites with LMWH. |
| Oxygen/supportive care | Treats clinically significant hypoxemia and reduces physiologic stress. | Titrate/support oxygen according to the order and patient condition; reassess SpO₂, respiratory effort, and clinical response. |
| Systemic thrombolysis | Rapid reperfusion for selected severe/high-risk PE, particularly with hemodynamic compromise. | Usually managed in a higher-acuity setting; bleeding and neurologic monitoring are critical. |
| Catheter-based therapy / thrombectomy | Selected patients may undergo catheter-directed thrombolysis or mechanical clot removal. | Monitor access site, distal perfusion, bleeding, hemodynamics, neurologic status, and post-procedure orders. |
| Surgical embolectomy | Surgical removal of clot for selected patients when indicated. | Requires ICU-level perioperative care and close hemodynamic/respiratory monitoring. |
| IVC filter | Considered mainly when anticoagulation cannot be given or in selected situations. | Know whether the filter is intended to be retrieved; ensure follow-up planning is not lost at discharge. |
Current 2026 multidisciplinary guidance emphasizes anticoagulation as the foundation of treatment for most acute PE, with advanced therapies reserved for selected higher-risk patients. When parenteral anticoagulation is needed, LMWH is generally preferred over UFH when there is no specific reason to choose UFH; DOACs are preferred over vitamin K antagonists for eligible patients.
6. Anticoagulation Nursing Care
- In the inpatient setting, the majority of patients will be on a continuous heparin infusion as part of the treatment for PE. Because of this, it is important to remember the considerations we have for administration of heparin (Reversal agent, how do we monitor therapeutic level, confirming with the provider how to discontinue infusion when transitioning to oral anticoagulant).
- Assess for active or occult bleeding: gums, urine, stool, emesis, skin, IV/access sites, new bruising, or unexpected hemoglobin/hematocrit changes.
- Review medication reconciliation carefully, including other agents that may increase bleeding risk.
- Monitor ordered laboratory studies and renal/hepatic function when relevant to the selected anticoagulant.
- Use bleeding precautions appropriate to the patient’s condition and institutional policy.
- Teach the patient why anticoagulation is prescribed: it prevents clot extension and recurrence; it does not instantly dissolve the existing clot.
- Reinforce that anticoagulants should be taken exactly as prescribed and that the patient should report significant bleeding or concerning new symptoms promptly.
| ALWAYS ASSESS BEFORE ADMINISTERING Before administering anticoagulant or thrombolytic therapy, verify the current clinical status, medication order, allergies, bleeding history/contraindications, relevant laboratory data, and required monitoring parameters. Follow the institution’s medication-specific protocol. |
7. Recognizing Clinical Deterioration
Escalate promptly for new or worsening:
- Hypotension or narrowing pulse pressure
- Rapidly increasing oxygen requirement or respiratory distress
- New syncope, altered mental status, or marked agitation
- Persistent or worsening tachycardia
- New chest pain or severe dyspnea
- Signs of poor peripheral perfusion
- Evidence of acute RV strain/failure or rapidly changing hemodynamics
A patient who becomes hemodynamically unstable has moved into a much higher-risk clinical state and may require emergent reperfusion or other advanced support.
8. Post-ICU Management: Transition Back to Medical-Surgical Care
Patients transferred from the ICU after severe PE may look substantially better while remaining vulnerable to recurrent VTE, bleeding, RV dysfunction, deconditioning, anxiety, and persistent dyspnea. The transition is therefore an active phase of care rather than simply a change in location.
| Priority | What the nurse should do |
| Respiratory recovery | Trend oxygen requirement, exertional symptoms, respiratory rate, and functional tolerance. Report worsening or unexplained persistent dyspnea. |
| Hemodynamic recovery | Monitor BP/HR and symptoms of recurrent RV strain. Compare trends with the ICU baseline. |
| Anticoagulation transition | Confirm the current anticoagulant, timing, planned duration, monitoring needs, and discharge regimen. |
| Bleeding surveillance | Continue assessment after thrombolysis/procedures and while anticoagulated. |
| Mobility | Advance activity according to the patient’s clinical status and orders; address deconditioning and fall risk. |
| Psychological recovery | Acknowledge fear/anxiety after a life-threatening PE and provide clear education and follow-up instructions. |
| Discharge planning | Ensure the patient understands medication adherence, warning signs, follow-up, and who to contact with concerns. |
| Long-term complications | Persistent dyspnea or exercise limitation warrants follow-up for post-PE syndrome, chronic thromboembolic disease, or CTEPH. |
Structured post-PE follow-up should reassess symptoms, anticoagulation, functional recovery, and possible chronic complications. Persistent or recurrent symptoms—especially after the early recovery period—should prompt clinical reassessment rather than being automatically attributed to deconditioning.
9. Patient Education Before Discharge
- Explain PE in plain language and review the purpose of anticoagulation.
- Review exactly how and when the prescribed medication is taken and what to do if a dose is missed according to the medication’s instructions.
- Teach bleeding precautions and symptoms that require urgent evaluation.
- Review symptoms of recurrent PE/DVT: sudden or worsening dyspnea, chest pain, syncope, coughing blood, or new unilateral leg swelling/pain.
- Emphasize follow-up appointments and the importance of reassessing anticoagulation duration rather than stopping therapy independently.
- Discuss activity progression and any individualized restrictions or recommendations from the treating team.
- For patients with persistent dyspnea or exercise intolerance, explain that further evaluation may be needed for chronic thromboembolic disease or post-PE syndrome.
10. Clinical Pearls
- PE is fundamentally a cardiopulmonary problem: think oxygenation + RV function + systemic perfusion.
- The most dangerous deterioration is acute RV failure leading to obstructive shock.
- Anticoagulation prevents clot propagation and recurrence; it does not immediately remove the clot.
- A stable blood pressure does not automatically mean a patient is low risk—RV dysfunction and biomarkers can identify patients needing closer observation.
- After ICU discharge, persistent dyspnea should be investigated rather than dismissed as ‘just deconditioning.’
- Medication education is a safety intervention: the patient needs to understand both recurrence prevention and bleeding risk.
References & Further Reading
1. Vyas V, Sankari A, Goyal A. Acute Pulmonary Embolism. StatPearls [Internet]. NCBI Bookshelf. Updated Dec. 11, 2024. https://www.ncbi.nlm.nih.gov/books/NBK560551/
2. American Heart Association. 2026 Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: Top Things to Know. Updated Feb. 19, 2026. https://professional.heart.org/en/science-news/2026-guideline-for-the-evaluation-and-management-of-acute-pulmonary-embolism-in-adults/top-things-to-know
3. Tomey M, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults. JACC, 2026.
4. Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the ERS. European Heart Journal. 2020;41:543-603.
5. Rivera-Lebron B, et al. Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. Clinical and Applied Thrombosis/Hemostasis. 2019.
6. Practical guide to management after an acute pulmonary embolism. BMJ Respiratory Research. 2025;12:e003028.
7. StatPearls. Catheter-Directed Thrombolysis of Pulmonary Embolism. NCBI Bookshelf.
